These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34453478)

  • 1. In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC).
    Kurmasheva RT; Erickson SW; Han R; Teicher BA; Smith MA; Roth M; Gorlick R; Houghton PJ
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29304. PubMed ID: 34453478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
    Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
    Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
    Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
    Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
    Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
    Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
    Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA
    Pediatr Blood Cancer; 2010 Dec; 55(6):1224-6. PubMed ID: 20979180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
    Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.
    Kurmasheva RT; Bandyopadhyay A; Favours E; Pozo VD; Ghilu S; Phelps DA; McGeehan GM; Erickson SW; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28284. PubMed ID: 32333633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
    Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
    Welch D; Kahen E; Fridley B; Brohl AS; Cubitt CL; Reed DR
    PLoS One; 2019; 14(9):e0222228. PubMed ID: 31550266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.